UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 12, 2024, Bolt Biotherapeutics, Inc. (the “Company”) held its 2024 annual meeting of stockholders (the “Annual Meeting”) to consider and vote on the two proposals set forth below, each of which is described in greater detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 26, 2024. A total of 38,127,740 shares of the Company's common stock were entitled to vote as of April 15, 2024, the record date for the Annual Meeting, of which 25,928,185 shares were represented in person or by proxy at the Annual Meeting. Proxies for the Annual Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition of management’s solicitation.
Nominee |
|
Votes For |
|
|
Votes Withheld |
|
|
Broker Non-Votes |
|
|||
Kathleen LaPorte |
|
|
12,706,287 |
|
|
|
3,990,176 |
|
|
|
9,231,722 |
|
Nicole Onetto, M.D. |
|
|
12,819,050 |
|
|
|
3,880,294 |
|
|
|
9,228,841 |
|
Votes For |
|
|
Votes Against |
|
|
Votes Abstaining |
|
|||
|
23,736,566 |
|
|
|
2,032,686 |
|
|
|
158,933 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Bolt Biotherapeutics, Inc. |
|
|
|
|
Date: |
June 14, 2024 |
By: |
/s/ William P. Quinn |
|
|
|
William P. Quinn |